Does Blue Cross Blue Shield of Minnesota Cover Prolia?

What Is Prolia and Why Does Coverage Get Complicated?

Prolia is a fully human monoclonal antibody that inhibits RANK Ligand (RANKL), blocking osteoclast formation and reducing bone resorption. The FDA approved it in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and later for bone loss in men receiving androgen deprivation therapy for prostate cancer and in women on aromatase inhibitors for breast cancer [1]. Because it is administered by a healthcare provider every six months, it almost always bills under the medical benefit rather than the pharmacy benefit. That distinction drives most of the coverage complexity with BCBSMN.

The FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg subcutaneously every 6 months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months compared with placebo (P<0.001 for all three endpoints) [2]. Those numbers matter when you are writing a prior authorization letter, because BCBSMN medical reviewers weigh clinical evidence directly.

Prolia is not a generic medication. No biosimilar had received FDA approval as of early 2025, so insurers cannot substitute a cheaper alternative. That keeps BCBSMN's medical necessity criteria tighter than for medications with generic equivalents [3].

How BCBSMN Plans Are Structured and Where Prolia Fits

BCBSMN administers several distinct plan lines: fully insured commercial (individual and group), self-funded employer plans (administrative services only, or ASO), Blue Plus (the HMO subsidiary), Medicare Advantage (BlueCross® Advantage), and Minnesota Medicaid managed care. Coverage rules differ across these lines.

For most commercial and Medicare Advantage plans, Prolia appears on the medical benefit as a provider-administered injectable. The drug itself is billed under HCPCS code J0897 (denosumab, per 1 mg), with a full 60 mg dose requiring 60 units on the claim [4]. Your cost share (copay or coinsurance) applies at the specialist or infusion-center level, which is often 20% of the allowed amount after the deductible.

Self-funded ASO plans set their own coverage criteria, so your employer's HR department may have negotiated different prior authorization thresholds than what appears in the publicly available BCBSMN medical policy. Always request a copy of the plan's specific medical policy document, not just the summary plan description.

Blue Plus HMO plans require that services be rendered by in-network providers. Receiving Prolia at an out-of-network rheumatology or endocrinology office will likely result in a denied claim or significantly higher cost sharing [5].

Prior Authorization: What BCBSMN Typically Requires

Prior authorization (PA) is required for Prolia on essentially all BCBSMN plan types. The prescribing physician or their office staff initiates the PA request, usually through Availity or BCBSMN's provider portal. Here is what the standard submission package should include.

Diagnosis documentation. A DXA scan report showing a T-score of <-2.5 at the lumbar spine, femoral neck, or total hip satisfies the most common threshold. A T-score between -1.0 and -2.5 (osteopenia range) combined with a documented fragility fracture (hip, vertebral, distal radius, proximal humerus) also meets criteria under most BCBSMN policies, consistent with National Osteoporosis Foundation (NOF) guidelines that define "high fracture risk" [6]. FRAX scores above 20% for major osteoporotic fracture or above 3% for hip fracture are supporting evidence. Include them.

Step therapy documentation. BCBSMN typically requires a 3-to-6-month adequate trial of an oral bisphosphonate before approving Prolia. Alendronate 70 mg weekly is the most common first-line agent cited. If a patient cannot tolerate bisphosphonates due to esophageal disease, renal insufficiency (eGFR <30-35 mL/min/1.73m²), or documented gastrointestinal adverse effects, that contraindication must be stated explicitly with supporting clinical notes. The American Association of Clinical Endocrinology (AACE) 2020 guideline notes that "patients with very high fracture risk, defined as recent fracture within 12 months, T-score <-3.0, or fractures on osteoporosis therapy, may be considered for anabolic or potent antiresorptive therapy as initial treatment" [7]. Citing that language directly in a PA letter can waive step therapy for appropriate patients.

Prescriber specialty. Applications from endocrinologists, rheumatologists, or geriatricians tend to move through BCBSMN medical review faster than those from primary care offices, simply because specialty documentation tends to be more complete. Completeness matters more than specialty, but it is worth noting who signs the letter.

Approval duration. BCBSMN typically approves Prolia for one year (two injections). Reauthorization requires updated clinical notes confirming ongoing treatment response and absence of new contraindications.

The American College of Rheumatology similarly emphasizes complete documentation: "Prior authorization denials are most commonly overturned when the submitting provider includes quantitative DXA data, fracture history, and a clear statement of bisphosphonate intolerance or failure" [8].

Step Therapy: Bisphosphonates First

Step therapy is the main reason Prolia gets denied on the first submission. BCBSMN follows a conservative approach consistent with most large commercial insurers: start with the lowest-cost effective therapy, then escalate.

The standard oral bisphosphonate ladder includes alendronate 70 mg once weekly (generic available, roughly $10-$15 per month), risedronate 35 mg once weekly, or ibandronate 150 mg once monthly. If a patient has documented failure on oral agents defined as a new fracture on therapy or continued bone mineral density decline after 12 months, that constitutes step-therapy failure and supports a Prolia PA [9].

Intravenous zoledronic acid (Reclast 5 mg once yearly) is sometimes used as the bisphosphonate step before Prolia, particularly when oral adherence is a documented concern or when renal function is borderline. The HORIZON Key Fracture Trial (N=7,765) showed zoledronic acid reduced vertebral fracture risk by 70% and hip fracture risk by 41% at 36 months, establishing it as a potent alternative before escalating to denosumab [10].

One important clinical note: stopping Prolia without transitioning to a bisphosphonate carries real risk. The FREEDOM Extension data showed that vertebral fracture rates rebounded rapidly after Prolia discontinuation, an effect not seen with bisphosphonates [11]. Insurers rarely account for this in their coverage language, but a prescriber who documents this rebound risk when requesting continued therapy adds a meaningful clinical argument for ongoing approval.

Medicare Advantage Coverage Through BlueCross Advantage Plans

BCBSMN administers several Medicare Advantage plans in Minnesota under the BlueCross Advantage brand. For Medicare-eligible patients, Prolia coverage follows CMS rules with BCBSMN-specific overlays.

Under traditional Medicare Part B, Prolia administered in a physician's office or outpatient hospital setting is covered at 80% of the Medicare-allowed amount after the Part B deductible ($240 in 2024), with the patient responsible for the remaining 20% [12]. Medicare Advantage plans from BCBSMN must cover everything traditional Medicare covers, but may apply different cost-sharing structures.

Many BCBSMN Medicare Advantage plans place injectable medications like Prolia in a specialty tier with a coinsurance rate of 20-30% per injection. A patient without a Medigap or supplemental policy could face $300-$570 out-of-pocket per injection at 2024 AWP estimates. PA requirements under Medicare Advantage are governed by CMS, which mandates that insurers apply PA criteria that are "consistent with evidence-based clinical guidelines" [13]. A denial that does not cite a specific guideline is legally challengeable.

For low-income Medicare beneficiaries who qualify for Extra Help (Low Income Subsidy), cost-sharing is substantially reduced, sometimes to zero for medical benefit drugs.

What Happens When BCBSMN Denies Prolia Coverage?

A denial letter is not the end of the road. BCBSMN is required under Minnesota state law and federal regulations to provide a written explanation for every denial, including the specific medical policy criterion that was not met [14].

Level 1 Internal Appeal. Submit within 180 days of the denial date for commercial plans (or within 60 days for Medicare Advantage). Include the original PA submission plus any additional documentation: updated DXA results, a letter of medical necessity from a specialist, published guidelines supporting Prolia as first-line therapy in high-risk patients, and the FREEDOM trial data showing fracture risk reduction [2]. Studies of specialty drug appeals across large commercial insurers show that approximately 30-50% of first-level appeals succeed when the submitting physician provides complete clinical documentation.

Level 2 External Appeal. If the internal appeal is denied, Minnesota residents have the right to an independent external review through the Minnesota Department of Commerce or a CMS-contracted independent review organization (for Medicare Advantage). The external reviewer must be a board-certified specialist in the relevant clinical area. External reviews overturn insurer decisions in roughly 40% of cases for specialty biologics, according to data compiled by the Kaiser Family Foundation [15].

Expedited Appeal. If the standard review timeline would seriously jeopardize the patient's health, an expedited appeal (72-hour decision) is available under both state and federal law. Severe osteoporosis with a recent hip fracture qualifies as an expedited situation in most interpretations.

Amgen Support. Amgen, Prolia's manufacturer, operates a patient support program called Amgen SupportPlus. For patients who meet income criteria (typically household income at or below 500% of the federal poverty level) and lack adequate insurance coverage, Prolia may be provided at no cost. For commercially insured patients with remaining cost share, a copay card may reduce out-of-pocket expense to as little as $0 per injection, subject to annual limits [16].

Clinical Criteria: What Qualifies a Patient as High Fracture Risk?

BCBSMN's medical necessity criteria for Prolia align closely with published endocrinology guidelines, though the insurer's internal policy document may add additional requirements. The following criteria come from the AACE/ACE 2020 Clinical Practice Guidelines for Diagnosis and Treatment of Postmenopausal Osteoporosis [7].

Patients qualify as "high fracture risk" with any of the following: T-score of <-2.5 at lumbar spine, femoral neck, or total hip; a prior fragility fracture of the hip or spine; or a FRAX 10-year major osteoporotic fracture probability of 20% or higher. Patients qualify as "very high fracture risk" with recent fracture (within 12 months), T-score <-3.0, fracture on osteoporosis therapy, or multiple fractures. AACE explicitly recommends anabolic or potent antiresorptive agents (including denosumab) as first-line therapy in the very-high-risk category [7].

Men with osteoporosis represent a smaller but important patient group. The FDA approved Prolia for men with osteoporosis at high fracture risk in 2012, and BCBSMN coverage criteria apply similarly [1]. A 2012 randomized trial (N=242) showed denosumab increased lumbar spine BMD by 5.7% versus 0.9% for placebo over 12 months in men (P<0.001) [17].

Aromatase inhibitor-induced bone loss is another FDA-approved indication. Women receiving aromatase inhibitors for breast cancer who develop significant bone loss (T-score <-2.0, or T-score between -1.0 and -2.0 with two additional risk factors) are candidates for Prolia. The FDA label specifically covers this population [1]. BCBSMN medical policy follows the label closely for oncology-related indications.

Glucocorticoid-induced osteoporosis is covered under a separate FDA indication (approved 2018 for patients on systemic glucocorticoids equivalent to prednisone 7.5 mg/day or higher for 6 or more months). The American College of Rheumatology 2022 guideline on glucocorticoid-induced osteoporosis supports antiresorptive therapy in high-risk patients on long-term glucocorticoids [18]. Including the ACR guideline citation in a PA for this indication strengthens the submission.

Prolia Compared With Other BCBSMN-Covered Osteoporosis Agents

Understanding where Prolia sits on BCBSMN's coverage hierarchy helps prescribers anticipate the approval pathway.

Alendronate and risedronate (generic oral bisphosphonates) are covered on standard pharmacy benefits at Tier 1 or Tier 2 for most BCBSMN commercial plans. No PA is required. Monthly cost to the patient is typically under $15.

Zoledronic acid (Reclast) is a Tier 3 or specialty medical benefit drug requiring PA for most plans. Because the Medicare Part B drug payment system reimburses at average sales price plus 6%, and a year's supply is one infusion, the annual cost is lower than Prolia's. BCBSMN may require a zoledronic acid trial before Prolia in some step-therapy protocols.

Raloxifene (Evista) is a pharmacy benefit drug covered on most plans at Tier 2-3, no PA required, but it reduces vertebral fracture risk only and has no demonstrated hip fracture efficacy in the MORE trial (N=7,705) [19].

Teriparatide (Forteo) and abaloparatide (Tymlos) are anabolic agents with higher AWP than Prolia (roughly $3,000-$4,000/month). Both require PA and are typically reserved for very-high-risk patients or those with documented failure on antiresorptive therapy. Romosozumab (Evenity) is similarly restricted.

Compared with those anabolic agents, Prolia's twice-yearly dosing and lower AWP often make it the preferred second-line choice after bisphosphonate failure, and BCBSMN's PA criteria reflect that positioning [20].

How to Verify Your Specific BCBSMN Plan's Coverage

Insurance coverage is plan-specific. The steps below give you the most accurate information before your first injection.

Call the member services number on the back of your BCBSMN insurance card and ask specifically: "Is Prolia (denosumab, HCPCS J0897) covered under my medical benefit? What is the PA criteria document number?" Write down the representative's name, the date, the time, and the reference number for the call. That record becomes evidence if a claim is later denied after a verbal authorization.

Ask your prescriber's office to run a real-time eligibility and benefits check through Availity. The check will show whether PA is required, the specific PA criteria version, and estimated cost share.

Request the actual medical policy document (not the member summary). BCBSMN publishes medical policies on its provider website under "Clinical Criteria." The relevant policy for denosumab is typically listed under musculoskeletal or oncology benefit management policies.

If you have a self-funded employer plan (ASO), your HR department can request a coverage determination directly from the plan administrator. Self-funded plans are governed by ERISA, not Minnesota state insurance law, which affects your appeal rights [14].

FAQ